SWAP70 as A Drug Target Or Biomarker for Various Diseases (G23075)

Target Name: SWAP70

NCBI ID: G23075

SWAP70

SWAP70 as A Drug Target Or Biomarker for Various Diseases

SWAP70, a switching B cell complex subunit, has recently been identified as a potential drug target or biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique function in the immune system has led to a growing interest in its potential as a therapeutic agent.

The immune system is a vital component of the body that protects against external threats, such as viruses, bacteria, and diseases. B cells, a type of immune cell, play a crucial role in generating antibodies to fight these pathogens. However, a malfunction in the B cell system can lead to the production of harmful antibodies, which can cause diseases such as cancer, autoimmune disorders, and neurodegenerative diseases.

One of the switches that regulate the activity of B cells is SWAP70. This protein is a subunit of the B cell complex, which is responsible for regulating the development and function of B cells. SWAP70 functions as a protein that can switch on and off various B cell signaling pathways, thereby regulating the production of antibodies and the activation of B cells.

Recent studies have suggested that SWAP70 may be a drug target or biomarker for various diseases. For example, several studies have shown that SWAP70 can be overexpressed or downregulated in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Overexpression of SWAP70 has been shown to promote the development and progression of cancer, while downregulation has been associated with the suppression of autoimmune responses.

In addition, SWAP70 has also been shown to be involved in the regulation of inflammation. During inflammation, SWAP70 has been shown to play a role in the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾. These cytokines are important for the recruitment of immune cells to the site of inflammation and the initiation of an inflammatory response.

Furthermore, SWAP70 has also been shown to be involved in the regulation of cellular signaling pathways. It has been shown to interact with several intracellular signaling proteins, including tyrosine kinase, NF-kappa-B, and JAK. These interactions may regulate various cellular processes, including cell growth, differentiation, and inflammation.

In conclusion, SWAP70 is a switching B cell complex subunit that has recently been identified as a potential drug target or biomarker for various diseases. Its unique function in the immune system has led to a growing interest in its potential as a therapeutic agent. Further research is needed to fully understand the role of SWAP70 in disease and to develop safe and effective treatments.

Protein Name: Switching B Cell Complex Subunit SWAP70

Functions: Phosphatidylinositol 3,4,5-trisphosphate-dependent guanine nucleotide exchange factor (GEF) which, independently of RAS, transduces signals from tyrosine kinase receptors to RAC. It also mediates signaling of membrane ruffling. Regulates the actin cytoskeleton as an effector or adapter protein in response to agonist stimulated phosphatidylinositol (3,4)-bisphosphate production and cell protrusion (By similarity)

The "SWAP70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SWAP70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets